

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 09555.0151USWO	Application Number: 10/576,439
	Applicant: Lussier et al.	
	Filing Date: January 5, 2007	Group Art Unit: 1654

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,458,764	10/2002	Gravel et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Copy of Written Opinion mailed March 2, 2005 from PCT Appln. No. PCT/CA2004/001843.				
		LIEBER, R.L. et al., "Growth Hormone Secretagogue Increases Muscle Strength during Remobilization after Canine Hindlimb Immobilization", Journal of Orthopaedic Research, 1997, vol. 15, pages 519-527.				
		THERATECHNOLOGIES INC., "Theratechnologies and Sakai Chemical sign landmark licensing agreement to develop and market ThGRF peptide in Japan", online, February 5 2002.				
		THERATECHNOLOGIES INC., "Theratechnologies announces positive results of an efficacy and safety phase II clinical trial of ThGRF in sleep maintenance insomnia", online, May 29 2002.				
		THERATECHNOLOGIES INC., "Theratechnologies clinically demonstrates improvement in immune function among elderly with ThGRF peptide", online, June 6 2002.				
		THERATECHNOLOGIES INC., "Theratechnologies: phase II clinical study completed in the United States", online, November 22 2002.				
		THERATECHNOLOGIES INC., "Theratechnologies: US phase II clinical study confirms safety of ThGRF in patients with Type II diabetes", online, January 29 2003.				
		THERATECHNOLOGIES INC., "Theratechnologies: financial results for the first quarter of 2003", online, April 17 2003.				
		THERATECHNOLOGIES INC., "Theratechnologies completes patients enrolment for its clinical study on chronic obstructive pulmonary disease as part of its phase II program on ThGRF", online, April 23 2003.				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 09555.0151USWO	Application Number: 10/576,439
	Applicant: Lussier et al.	
	Filing Date: January 5, 2007	Group Art Unit: 1654

		THERATECHNOLOGIES INC., "Theratechnologies initiates phase II clinical trial in Canada and the US for ThGRF in HIV-related lipodystrophy", online, May 22 2003.
		THERATECHNOLOGIES INC., "Theratechnologies presents data on its development programs at the 85th annual meeting of the endocrine society", online, June 10 2003.
		THERATECHNOLOGIES INC., "Theratechnologies presents data on its development programs at the 85th annual meeting of the endocrine society", online, June 20 2003.
		THERATECHNOLOGIES INC., "Theratechnologies: patient enrolment completed in hip fracture phase II clinical for ThGRF", online, July 9 2003.
		THERATECHNOLOGIES INC., "Theratechnologies: financial results for the second quarter of 2003", online, July 14 2003.
		THERATECHNOLOGIES INC., "Theratechnologies: financial results for the third quarter of 2003 and recent operating highlights", online, April 17 2003.

**23552**

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	